arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Spero Therapeutics, Inc.

SPRO
$1.01 ▼ -0.05 (-4.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Bullish
auto_awesome

Analytical Summary

Spero Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $56.6M
Dividend Yield —
Revenue Growth 39.2% ↗
Op. Margin 9.5% ↗
ROIC 10.4% ↗
FCF / Share $-0.23 ↗
Trailing P/E 6.7x
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$66.80M
↑ +39.2% —
Net Income Profit after all expenses
$8.57M
↑ +112.5% —
Operating Margin Operating profit as % of sales
9.5%
↑ +106.2% 55th
FCF / Share Free cash flow per share
$-0.23
↑ +48.1% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
45
Returns
79
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 46 quarters